Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain

Inclusion Criteria: * Agree to participate in the study and give written informed consent * Subjects must have chronic low back pain with a high probability of a significant neuropathic component during 4 years or less (but not less than 3 months) * Patients with chronic low back pain reported as moderate to severe intensity (EVA ≥ 40 mm) * Patients with Neuropathic Pain Questionnaire (DN4) result ≥ 4 * Women of childbearing potential under a medically acceptable method of contraception Exclusion Criteria: * Patients participating in another clinical trial involving an investigational treatment or participation in one within 4 weeks prior to study start * Patients whose participation in the study may be influenced (employment relationship with the research site or sponsor, inmates, etc.) * At medical discretion, a disease that affects prognosis and prevents outpatient management, for example, but not limited to: end-stage cancer, kidney, heart, respiratory or liver failure, mental illness or with scheduled surgical or hospital procedures * History/presence of any disease or condition that, in the opinion of the Investigator, could pose a risk for the patient or confusing the efficacy and safety of the investigational product * Patients in whom the study drug is contraindicated for medical reasons * Patients with allergy or hypersensitivity to the active substance of the study drugs, related products or excipients * Pregnant women, women breastfeeding or planning a pregnancy during the conducting the study * Significant history of gastrointestinal diseases (e.g., gastric ulcer, Crohn's disease, Ulcerative Colitis, etc.) * Current treatment with opioids and/or NSAIDs including COX-2 inhibitors (except celecoxib), reported in clinical history in the last 24 hours to the signing of the informed consent * Patients who are receiving monoamineoxidase inhibitors (MAOIs) or who have received them in the course of the 2 weeks prior to signing the informed consent * Patients with a history of alcohol or drug abuse in the last year * Patients with a history of ischemic heart disease, peripheral artery disease, and/or cerebral vascular disease (including patients who have recently undergone coronary revascularization or angioplasty) * Patients with a history of seizures, epileptic status and/or grand mal seizures * History of chronic liver failure Child-Pugh A, B, and/or C * History of acute renal failure (glomerular filtration rate \<30 ml/min/1.72 m2) * Patient with …